Teclistamab achieves 95% hematologic response in relapsed/refractory AL amyloidosis patients
Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.
Abstract
Teclistamab achieved a 95% hematologic response at 3 months in 52 patients with relapsed/refractory AL amyloidosis, showing strong efficacy.